Minimising body weight gain in insulin treatment

Details Minimising body weight gain in insulin treatment Minimising body weight gain in insulin treatment

2011-08-23

2011-08-23

Cordero Garcia, Marcela M (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

08003605

ABSTRACT:
A method for minimizing weight gain, preventing weight gain or inducing weight loss in a mammal, said method involving a treatment regimen which comprises administration of an insulin derivative having a substituent containing from 6 to 40 carbon atoms attached to one of its amino acid residues.

REFERENCES:
patent: 6136784 (2000-10-01), L'Italien et al.
patent: 6174856 (2001-01-01), Langballe et al.
patent: 6451970 (2002-09-01), Schaffer et al.
patent: 2003/0171535 (2003-09-01), Schaffer et al.
patent: 2003/0224973 (2003-12-01), Bayer et al.
patent: WO 97/31022 (1997-08-01), None
Definition of derivative. (http://www.answers.com/derivative&r=67) accessed online Nov. 10, 2005. 1 page.
Rudinger. In: Peptide Hormones, JA Parsons, Ed. (1976) pp. 1-7.
Sigma: Designing Custom Peptides, http://www.sigma-genosys.com/peptide—design.asp (accessed online Dec. 16, 2004) 2 pages.
Berendsen. A Glimpse of the Holy Grail? Science (1998) vol. 282, pp. 642-643.
Voet et al. Biochemistry, 2nd edition (1995) pp. 235-241.
Smilek et al. A single amino acid change in a myelin basic protein oeptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. PNAS USA. 1991, vol. 88, pp. 9633-9637.
Messer. Vasopressin and Oxytocin, web document updated Apr. 3, 2000, http://www.neurosci.pharm.utoledo.edu/MBV3320/vasopressin.htm, 5 pages.
Axelsen et al. More Predictable Fasting Blood Glucose with the New Soluble Basal Insulin Analogue, Insulin Detemir: A Comparison with NPH in Type I Diabetes Patients. Diabetes Research and Clinical Practice. Sep. 2000, vol. 50, No. Suppl. 1, p. S79.
Brunner et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp Clin Endocrinal Diabetes 2000, 108, pp. 100-105.
Calculate your BMI—Standard BMI Calculator at http://www.nhlbisuppport.com/bmi accessed online Aug. 15, 2006.
Standl. Insulin Analogues—State of the Art. Hormone Res 2002; 57 (suppl 1) pp. 40-45.
Simpson et al. Insulin aspart. Drugs May 1999, vol. 57, No. 5, pp. 759-765.
White. The Pharmacological Reduction of Blood Glucose in Patients With Type 2 Diabetes Mellitus. Clinical Diabetes, 1998, vol. 12, No. 2, pp. 58-67.
Bognetti et al. Prevalence and correlates of obesity in insulin dependent diabetic patients. Archives of Disease in Childhood. 1995. vol. 73, pp. 239-242.
Detournay et al. Diabetes and Metabolism. Managing type 2 diabetes in France: the ECODIA survey. 2000. vol. 26, No. 5, pp. 1-19.
Kraine et al. The Role of Environmental Factors in Insulin-Dependent Diabetes Mellitus: An Unresolved Issue. Environmental Health. 1999. vol. 107, Supplement 5., pp. 777-781.
Levemir® insulin detemir (rDNA origin) injection. Novo Norkisk. Date of Issue: May 16, 2007, pp. 1-2.
Atkinson et al. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. The Lancet. vol. 358, Jul. 21, 2001, pp. 221-229.
Influence of Intensive Diabetes Treatment on Body Weight and Composition of Adults With Type 1 Diabetes in the Diabetes Control and Complications Trial, Diabetes Care, vol. 24, No. 10, pp. 1711-1721, Oct. 2001.
Memorandum Opinion (Sanofi-Aventisv.Novo Nordisk Inc., Civil Action No. 06-1369.
Memorandum Of Novo Nordisk Inc., In Opposition To Plaintiff's Motion For a Preliminary Injunction, Apr. 7, 2006.
Declaration of Alan C. Moses, M.D, dated Apr. 6, 2006.
Declaration of Brian Blakey, dated Apr. 5, 2006.
Declaration of Lene Andersen, dated Apr. 5, 2006.
Declaration of Wayne Pines, dated Apr. 5, 2006.
Sanofi-Aventis' Complaint against Novo Nordisk; Mar. 23, 2006.
Declaration of John E. Timberlake, dated Mar. 22, 2006.
Declaration of John E. Gerich, M.D., dated Mar. 22, 2006.
Kurtzhals et al, Diabetes, 2000, vol. 49, No. 6, pp. 999-1005.
Vague et al., Diabetes Care, 2003, vol. 26, No. 3, pp. 590-596.
Standl et al., 38thAnnual Meeting of EASD, 1 Sep. 1, 2002, Budapest, Hungary, XP002243151.
Slee, PR Newswire: Immedia.IT/Puglished/20010910/2001091016194, “Study Shows Insulin Detemir Controls Blood Glucose Levels More Predictably”, 2001, XP002243152.

Affiliated with

Also associated with

Rating

Minimising body weight gain in insulin treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Minimising body weight gain in insulin treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Minimising body weight gain in insulin treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2635102